Ferdinand Groenewald's most recent trade in Biosig Technologies Inc was a trade of 35,000 Common Stock done . Disclosure was reported to the exchange on April 24, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Biosig Technologies Inc | Ferdinand Groenewald | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 35,000 | 60,000 (0%) | 0% | 0 | Common Stock | |
Alaunos Therapeutics Inc | Ferdinand Groenewald | VP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2025 | 3,000 | 3,000 | - | - | Employee Stock Option (right to buy) | |
Alaunos Therapeutics Inc | Ferdinand Groenewald | VP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2024 | 1,500 | 1,500 | - | - | Employee Stock Option (right to buy) | |
Sadot Group Inc | Ferdinand Groenewald | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 25,000 | 25,000 | - | - | Stock Options | |
Sadot Group Inc | Ferdinand Groenewald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Feb 2022 | 19,285 | 0 | - | 0.6 | 11,185 | Common Stock |
Sadot Group Inc | Ferdinand Groenewald | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.87 per share. | 11 Feb 2021 | 19,285 | 19,285 | - | 2.9 | 55,348 | Common Stock |
Sadot Group Inc | Ferdinand Groenewald | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 24 Jul 2020 | 19,285 | 0 | - | 0 | Common Stock |